As of close on Monday, 3/21, PKTX saw several lines of potential support strengthening.
Those include its:
- 5-Day Simple Moving Average (SMA)
- 20-Day SMA
- 5-Day Exponential Moving Average (EMA)
- 13-Day EMA
Additionally, PKTX's 5-Day EMA is trading above its 13-Day EMA in what can be considered a bullish manner.
Watch these lines of potential support closely.
-----
No. 2 PKTX Potential Catalyst - Company Selects Two AAGP Formulations To Advance Into Preclinical Efficacy Testing
ProtoKinetix Announces Selection of AAGP Candidate Formulations for Treatment of Dry Eye Disease
MARIETTA, Ohio, November 23, 2021--(BUSINESS WIRE)--ProtoKinetix, Incorporated (the "Company" or "ProtoKinetix") (OTCQB: PKTX), a clinical-stage biomedical company, today announced that it has selected two formulations of its Anti-Aging Glycopeptide (AAGP) product to be advanced into preclinical efficacy testing for the topical treatment of dry eye disease and ocular inflammation.
The selection follows a seven-month formulation development program conducted by Catalent, in which the Active Pharmaceutical Ingredient (API) was screened for ideal formulation conditions, with a number of potential excipients, to come up with a drug product that suits ProtoKinetix’s needs. The efficacy testing will be conducted by EyeCRO of Oklahoma City. This study should be completed by mid to late January 2022. The resulting lead formulation will then undergo extensive Good Laboratory Practice (GLP) toxicology examination, to prepare a submission for the U.S. FDA for its approval to conduct clinical trials.
[...]
Read the full article here.
-----
No. 3 PKTX Potential Catalyst - Partnering With NYSE Company To Accelerate Development Of AAGP
ProtoKinetix and IQVIA Partner to Support Development of AAGP Product in the Treatment of Ocular Conditions
ProtoKinetix, Incorporated (the "Company" or "ProtoKinetix") (OTCQB: PKTX), a clinical-stage biomedical company, today announced its collaboration with IQVIA (NYSE: IQV) to accelerate development of AAGP (PKX-001) in ocular conditions, specifically Dry Eye Disease and Wet and Dry forms of Age-related Macular Degeneration.
The ProtoKinetix-IQVIA collaboration will aim to accelerate the clinical development and regulatory progress of PKX-001. The collaboration is expected to drive directed clinical development as PKX-001 enters Phase 1 testing for the above conditions. This initiative will also serve to optimize these clinical trials to determine safety in these new conditions, drawing from previous experience with PKX-001 in Type 1 diabetes and other conditions.
Read the full article here.
-----
No. 4 PKTX Potential Catalyst - Resumption Of Phase 1b Clinical Trials For Use Of AAGP Treated Islet Cells
ProtoKinetix Announces the Resumption of Phase 1b Clinical Trials for the use of AAGP Treated Islet Cells in the Treatment of Type 1 Diabetes
ProtoKinetix, Incorporated (the "Company" or "ProtoKinetix") (OTCQB: PKTX), a clinical-stage biomedical company, today announced Phase I clinical trials of AAGP (PKX-001) treated islet cells have resumed at the University of Alberta, Edmonton. All clinical trials were paused in 2020 due to CV-19 restrictions in the province.
[...]
Read the full article here.
-----
No. 5 PKTX Potential Catalyst - Peer Reviewed Research Publication Interpreting Results Examining Benefit Provided By AAGP
Journal of Tissue Engineering and Regenerative Medicine Publishes Peer Reviewed Research Paper Establishing ProtoKinetix AAGP Enhanced Stem Cell Vision Restoration
ProtoKinetix, Incorporated (the "Company" or "ProtoKinetix") (OTCQB: PKTX), a clinical-stage biomedical company, today announced the publication of a peer reviewed research paper describing and interpreting the results examining the benefit provided by AAGP to enable human induced pluripotent stem cell (iPSC) derived retinal precursor cells transplanted to restore vision in an experimental model of blindness due to retina degeneration. The paper has been published by the prestigious Journal of Tissue Engineering and Regenerative Medicine. The focus of this journal is therapeutic approaches which combine stem/progenitor cells with bioactive agents to restore, maintain, or improve tissue or organ function.
[...]
Read the full article here.
-----
PKTX Recap: 5 Potential Catalysts To Know Now
No. 1 - Potential Support Levels Could Be Strengthening
No. 2 - Company Selects Two AAGP Formulations To Advance Into Preclinical Efficacy Testing
No. 3 - Partnering With NYSE Company To Accelerate Development Of AAGP
No. 4 - Resumption Of Phase 1b Clinical Trials For Use Of AAGP Treated Islet Cells
No. 5 - Peer Reviewed Research Publication Interpreting Results Examining Benefit Provided By AAGP
-----
Coverage is officially initiated on PKTX. When you have a moment, do this:
